Perceptive Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Perceptive Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-440,000	Closed	-$14.4M	–	155
2018 Q1	$14.4M	Buy	+440,000	New	+$19.3M	0.4%	53
2017 Q4	–	Sell	-7,870	Closed	-$425K	–	166
2017 Q3	$425K	Hold	7,870	–	–	0.02%	128
2017 Q2	$442K	Sell	7,870 -50,000	-86%	-$2M	0.02%	118
2017 Q1	$2.27M	Buy	+57,870	New	+$1.84M	0.13%	80
2015 Q3	–	Sell	-111,103	Closed	-$5.06M	–	199
2015 Q2	$5.06M	Sell	111,103 -243,897	-69%	-$9.81M	0.3%	64
2015 Q1	$13.5M	Buy	355,000 +330,000	+1,320%	+$11.3M	1.05%	25
2014 Q4	$708K	Buy	+25,000	New	+$695K	0.06%	109

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Perceptive Advisors's PTLA Position: Q2 2018 in Review

Perceptive Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2018, closing a stake of 440,000 shares — an estimated $14.4M sold.

Perceptive Advisors first reported a position in PTLA in Q4 2014 and held it in 7 quarters. The position peaked at $14.4M in Q1 2018. 204 funds tracked by Wall St. Rank hold PTLA as of Q2 2018.

Perceptive Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Perceptive Advisors sold 440,000 Portola Pharmaceuticals, Inc. shares in Q2 2018, an estimated $14.4M.
Perceptive Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
Perceptive Advisors's Portola Pharmaceuticals, Inc. position peaked at $14.4M in Q1 2018.
204 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.